ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
ADMA Biologics (Nasdaq: ADMA) has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after U.S. financial markets close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADMA Biologics (Nasdaq: ADMA) has scheduled its fourth quarter and full year 2024 financial results announcement for March 3, 2025, after U.S. financial markets close. The company's management team will host a conference call and audio webcast at 4:30 p.m. ET on the same day to discuss financial results and provide company updates.
Interested participants can access the conference call by dialing (888) 596-4144 with conference ID 5201334. It's recommended to join approximately 10 minutes before the event starts. Those not planning to ask questions are encouraged to listen to the live webcast available on the company's website. An archived replay will be available in the investor section under "Events & Webcasts" at ir.admabiologics.com/events-webcasts.
ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics.
Details
News Market Reaction – ADMA
The recorded move for ADMA in the trading session of this news was -0.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call, please dial (888) 596-4144 and refer to conference ID 5201334. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.